T. Rowe Price Associates
FDMT icon

T. Rowe Price Associates’s 4D Molecular Therapeutics FDMT Stock Holding History

T. Rowe Price Associates’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396K Buy
42,447
+3,700
+10% +$32.2K ﹤0.01% 2547
2025
Q4 		$291K Sell
38,747
-6,281
-14% -$63.7K ﹤0.01% 2659
2025
Q3 		$392K Buy
45,028
+9,700
+27% +$58K ﹤0.01% 2469
2025
Q2 		$132K Buy
35,328
+8,800
+33% +$30.9K ﹤0.01% 2836
2025
Q1 		$86K Sell
26,528
-18
-0.1% -$85 ﹤0.01% 2855
2024
Q4 		$148K Sell
26,546
-3,989
-13% -$31.3K ﹤0.01% 2770
2024
Q3 		$331K Buy
30,535
+491
+2% +$8.15K ﹤0.01% 2431
2024
Q2 		$631K Buy
30,044
+6,092
+25% +$153K ﹤0.01% 2097
2024
Q1 		$764K Buy
23,952
+1,356
+6% +$34.6K ﹤0.01% 2025
2023
Q4 		$458K Buy
22,596
+1,106
+5% +$14.6K ﹤0.01% 2214
2023
Q3 		$274K Buy
21,490
+2,570
+14% +$43K ﹤0.01% 2370
2023
Q2 		$342K Buy
18,920
+539
+3% +$9.92K ﹤0.01% 2307
2023
Q1 		$316K Buy
18,381
+1,002
+6% +$19.5K ﹤0.01% 2322
2022
Q4 		$386K Sell
17,379
-729
-4% -$11.3K ﹤0.01% 2267
2022
Q3 		$146K Buy
18,108
+2,318
+15% +$21K ﹤0.01% 2634
2022
Q2 		$110K Buy
15,790
+4,415
+39% +$42.9K ﹤0.01% 2738
2022
Q1 		$172K Buy
11,375
+700
+7% +$11K ﹤0.01% 2745
2021
Q4 		$234K Buy
+10,675
New +$262K ﹤0.01% 2700
2021
Q2 		– Sell
-279,746
Closed -$12.1M – 2932
2021
Q1 		$12.1M Sell
279,746
-63,932
-19% -$2.83M ﹤0.01% 1364
2020
Q4 		$14.2M Buy
+343,678
New +$14.2M ﹤0.01% 1297

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates's FDMT Position: Q1 2026 in Review

T. Rowe Price Associates increased its 4D Molecular Therapeutics (FDMT) stake by 9.5% in Q1 2026, buying an estimated $32.2K and bringing the position to 42,447 shares worth $396K. The position accounts for ﹤0.01% of the portfolio, ranked #2547.

T. Rowe Price Associates first reported a position in FDMT in Q4 2020 and has held it in 20 quarters since. The position peaked at $14.2M in Q4 2020. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • T. Rowe Price Associates held 42,447 shares of 4D Molecular Therapeutics worth $396K as of Q1 2026.
  • T. Rowe Price Associates bought 3,700 4D Molecular Therapeutics shares in Q1 2026, an estimated $32.2K.
  • 4D Molecular Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2547 holding.
  • T. Rowe Price Associates first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • T. Rowe Price Associates's 4D Molecular Therapeutics position peaked at $14.2M in Q4 2020.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.